Literature DB >> 25973061

Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells.

Yandong Li1, Yongli Zhou2, Jianyun Zheng1, Chunyan Niu2, Bing Liu1, Meini Wang1, Hangrong Fang1, Chuan Hou1.   

Abstract

Gastric cancer is the second leading cause of cancer-related death worldwide. Survivin overexpressed in many human cancers as a member of the inhibitor of apoptosis protein family. We found that all samples of normal gastric tissues did not express the protein of survivin, and however, 65% human gastric cancer samples expressed survivin. Positive expression of survivin correlated with differentiation. The proliferation and migration of gastric cancer decreased after downregulation of surviving by RNA interference. Furthermore, downregulation of survivin caused the cell cycle arrest. These suggest that survivin play an important role in gastric cancer and the use of survivin siRNA might become an effective approach to cancer therapy.

Entities:  

Keywords:  Survivin; cell cycle; gastric cancer; migration; proliferation

Mesh：

Substances：

Year:  2015        PMID： 25973061      PMCID： PMC4396289     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


  20 in total

Review 1.  Validating survivin as a cancer therapeutic target.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

Review 2.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

Authors:  F P Kuhajda
Journal:  Nutrition       Date:  2000-03       Impact factor: 4.008

3.  Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance.

Authors:  Mei Cao; Shang-Mian Yie; Sheng-Min Wu; Shu Chen; Be Lou; Xu He; Shang-Rong Ye; Ke Xie; Lin Rao; En Gao; Nai-Yao Ye
Journal:  Clin Exp Metastasis       Date:  2009-06-12       Impact factor: 5.150

4.  Regulation of microtubule stability and mitotic progression by survivin.

Authors:  Alessandra Giodini; Marko J Kallio; Nathan R Wall; Gary J Gorbsky; Simona Tognin; Pier Carlo Marchisio; Marc Symons; Dario C Altieri
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

5.  Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells.

Authors:  Md Motarab Hossain; Naren L Banik; Swapan K Ray
Journal:  Exp Cell Res       Date:  2012-04-10       Impact factor: 3.905

6.  High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma.

Authors:  Noyko Stanilov; Lyuba Miteva; Nikolay Mintchev; Spaska Stanilova
Journal:  Int J Colorectal Dis       Date:  2008-09-30       Impact factor: 2.571

7.  An anti-apoptosis gene, survivin and telomerase expression in gastric cancer.

Authors:  Akira Tsuburaya; Yoshikazu Noguchi; Takaki Yoshikawa; Aya Saito; Chiharu Doi; Takahide Okamoto; Kuniyasu Fukuzawa
Journal:  Hepatogastroenterology       Date:  2002 Jul-Aug

Review 8.  Survivin, versatile modulation of cell division and apoptosis in cancer.

Authors:  Dario C Altieri
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

9.  The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR.

Authors:  ChangXin Shen; LiHua Hu; Lin Xia; YiRong Li
Journal:  Clin Biochem       Date:  2008-11-06       Impact factor: 3.281

Review 10.  Role of survivin and its splice variants in tumorigenesis.

Authors:  F Li
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640
View more
  8 in total

1.  Hydroxyflavanone inhibits gastric carcinoma MGC-803 cell proliferation.

Authors:  Haiyan Zhang; Zhuo Zhan; Mingfu Cui; Yongjian Gao; Dayu Wang; Ye Feng
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity.

Authors:  Arash Latifkar; Lu Ling; Amrit Hingorani; Eric Johansen; Amdiel Clement; Xiaoyu Zhang; John Hartman; Claudia Fischbach; Hening Lin; Richard A Cerione; Marc A Antonyak
Journal:  Dev Cell       Date:  2019-04-11       Impact factor: 12.270

3.  Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway.

Authors:  Jolene Caifeng Ho; Lissa Nurrul Abdullah; Qing You Pang; Sudhakar Jha; Edward Kai-Hua Chow; Henry Yang; Hiroyuki Kato; Lorenz Poellinger; Jun Ueda; Kian Leong Lee
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

4.  Construction of a novel vector expressing Survivin-shRNA and fusion suicide gene yCDglyTK and its application in inhibiting proliferation and migration of colon cancer cells.

Authors:  Ling Ye; Yuan Yang; Xin-Yu Ma; Dan Li; Mei-Li Xu; Pan Tan; Li-Min Long; Hai-Qin Wang; Ting Liu; Yong-Hong Guo
Journal:  Exp Ther Med       Date:  2017-09-20       Impact factor: 2.447

5.  The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.

Authors:  Matthew Brown; Wanbin Zhang; Deyue Yan; Rajath Kenath; Le Le; He Wang; Daniel Delitto; David Ostrov; Keith Robertson; Chen Liu; Kien Pham
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.752

6.  Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.

Authors:  Samia S Messeha; Najla O Zarmouh; Abrar Asiri; Karam F A Soliman
Journal:  Nutrients       Date:  2020-12-07       Impact factor: 5.717

7.  hnRNPA2B1 regulates the alternative splicing of BIRC5 to promote gastric cancer progression.

Authors:  Wei-Zhao Peng; Jin Zhao; Xin Liu; Chao-Feng Li; Shuang Si; Ren Ma
Journal:  Cancer Cell Int       Date:  2021-05-27       Impact factor: 5.722

8.  Tumor promoter role of miR‑647 in gastric cancer via repression of TP73.

Authors:  Xiangqian Zhang; Min Zhang; Guifeng Wang; Ye Tian; Xiaolong He
Journal:  Mol Med Rep       Date:  2018-08-06       Impact factor: 2.952
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.